BeiGene Declares Acceptance of twelfth Regulatory Submission in China for PD-1 Inhibitor Tislelizumab Submission seeks advertising and marketing authorization for first-line remedy of unresectable or metastatic hepatocellular carcinoma CAMBRIDGE, Mass.,…

PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a personal, clinical-stage most cancers immunotherapy firm growing novel biotherapeutics concentrating on myeloid checkpoints as we speak introduced the shut of a further…

BEIJING–(BUSINESS WIRE)–Biocytogen Prescribed drugs (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) formally launched its totally human heavy chain antibody platform, RenNano®. RenNano® is the third member of the RenMice™ household, becoming…

BioSpectrum interacted with just a few leaders from main market segments of the trade who offered their insights into what the approaching yr is more likely to maintain for his…